On Monday, H.C. Wainwright began coverage on Sanara MedTech Inc. (NASDAQ: SMTI) with a Buy rating and set a price target of $50.00 per share, representing nearly 50% upside from the current price of $33.68. The firm's analyst highlighted the company's focus on developing and commercializing medical technology aimed at improving clinical outcomes in surgical and chronic wound care, while also aiming to reduce healthcare costs. According to InvestingPro data, analysts maintain a Strong Buy consensus on the stock.
The analyst noted that Sanara MedTech's revenue growth has been driven by its commercialized surgical wound care products since 2019, with InvestingPro data showing impressive revenue growth of 24.66% and industry-leading gross margins of 90.16%.
The firm believes that Sanara MedTech's strategy of market penetration and geographic expansion is likely to continue propelling topline growth in upcoming quarters.
Furthermore, Sanara MedTech is investing in its Tissue Health Plus (THP) program, which is designed to address the extensive post-acute wound care market. A pilot THP program is expected to begin in the first half of 2025, with a commercial launch anticipated by mid-2025.
Additionally, the company's joint venture is preparing to introduce a new product intended for the treatment of oral mucositis, a common complication of chemotherapy and radiation therapy. The analyst expressed a positive outlook on the company's comprehensive strategy, anticipating it will lead to significant growth in revenue and EBITDA in the future.
In summary, H.C. Wainwright's coverage initiation reflects a positive view of Sanara MedTech's growth prospects, backed by its strategic initiatives and product pipeline. The firm's $50 price target reflects a 12-month forecast for the stock's performance. InvestingPro analysis shows the company maintains a GOOD overall financial health score, with 8 additional key insights available to subscribers, including detailed valuation metrics and growth indicators.
In other recent news, Sanara MedTech reported a 35% increase in its third-quarter revenue for 2024, reaching a net revenue of $21.7 million. This marks the 12th consecutive quarter of record earnings for the company. The adjusted EBITDA also saw growth, rising to $800,000 from $300,000 in the same quarter the previous year.
Despite these positive developments, Sanara's Surgical and Tissue Health Plus segments reported net losses. The company has also made strategic investments, including acquiring a stake in ChemoMouthpiece LLC and planning a commercial launch for its THP technology platform in mid-2025. These are among the latest developments for Sanara MedTech.
However, no specific financial expectations for the ChemoMouthpiece product were provided during the call. The company's overall revenue has increased from $47 million to $60 million year-over-year, with a focus on maintaining strong cash flow. Sanara MedTech is also progressing with its growth strategy and market expansion plans, particularly in the non-acute wound care market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.